Drug Profile
Research programme: viral haemorrhagic fever therapeutics - Alnylam/USAMRIID
Alternative Names: VP35 siRNA - AlnylamLatest Information Update: 22 Oct 2013
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals; United States Army Medical Research Institute of Infectious Diseases
- Class Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Viral haemorrhagic fevers
Most Recent Events
- 22 Oct 2013 Discontinued - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
- 31 Dec 2011 No development reported - Preclinical for Viral haemorrhagic fevers in USA (Parenteral)
- 07 Aug 2008 Alnylam is awarded continued funding of $US7.5 million from the US NIAID to support development of an RNAi therapeutic against viral haemorrhagic fevers (including Ebola)